Diabetes in Latin America 2026: The control gap

HealthSignals Special Report · 17 pages · Brazil, Mexico, Argentina, Colombia, Chile and Peru

Most Latin American patients diagnosed with diabetes are on treatment. Far fewer reach their glycaemic target. This report maps that control gap across the region’s six largest markets and what it means for manufacturers, payers and health ministries.

Main findings

  • Treatment is common, control is not. Among diagnosed adults in Mexico, 90.9% are on drug treatment, but only 33.0% reach an HbA1c (glycated haemoglobin) below 7% (actual, 2021–24; Encuesta Nacional de Salud y Nutrición, Ensanut Continua 2021–2024).
  • Brazil’s last measured cascade ends in a similar place: 22.5 controlled patients per 100 with diabetes (actual, 2014–15; Pesquisa Nacional de Saúde, PNS 2014/2015). That data is now eleven years old.
  • The burden is concentrated. The International Diabetes Federation (IDF) models 16.6 million adults with diabetes in Brazil and 13.6 million in Mexico (estimate, 2024).
  • Out-of-pocket costs vary widely: 41.2% of current health expenditure in Mexico against 14.6% in Colombia (actual, 2023; WHO Global Health Expenditure Database).
  • Few markets measure the full cascade. Only two of the region’s six largest markets publish a measured national care cascade, and about a third of patients are still never diagnosed.

Exhibit 1

Of every 100 people with diabetes, about 22 are under control in both markets that measure it

The care cascade, per 100 people with diabetes · Mexico (actual, 2021–24) and Brazil (actual, 2014–15)

Mexico · Ensanut Continua 2021–24Brazil · PNS 2014/2015
Have diabetes
100
Know they have it
68.2
68.2
On drug treatment
62.0
62.9
At HbA1c below 7%
22.5
22.5
  1. Chained from the published steps. Mexico: 11.6 of 17.0 points diagnosed = 68.2; × 90.9% treated = 62.0; × 33.0% controlled = 22.5. Brazil: 68.2 knew; × 92.2% treated = 62.9; × 35.8% controlled = 22.5.
  2. Denominators differ: Mexico’s control figure is denominated on diagnosed patients, Brazil’s on treated patients. The surveys are nine years apart.
Source: Reyes-García A, et al. Salud Pública de México 2025;67(6):622-632; Tonaco LAB, et al. Revista de Saúde Pública 2023;57:75. Both actual measurements.

The HealthSignals view

Value moves from finding patients to keeping them at target. The full report sets out what that shift means for 2026–2030, with a spotlight on each market.

Get the full report

Free. The report is emailed to you, and downloading it subscribes you to The HealthSignals Brief, our fortnightly PDF. Unsubscribe anytime. Work email for instant access; personal email addresses are reviewed by our editor within a week.

THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.